RecruitingEpstein-Barr Virus

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Eligible age

18–30 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Sponsor: ModernaTX, Inc.

✓ Healthy as determined by medical evaluation including medical history and physical examination.
✓ Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast/chest feeding.

✕ Have undergone surgical procedures within 7 days prior to Day 1 or Day 57 or are scheduled to undergo a surgical procedure within 28 days after study intervention administration.
✕ Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infectious disease.
✕ Received corticosteroids at ≥10 milligrams per day (mg/day) of prednisone or equivalent for \>14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study.
✕ Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses, within 180 days prior to Day 1 or plans to do so during the study.
✕ Received or plans to receive any nonstudy vaccine from 28 days prior to first dose/Day 1 up to 28 days after the second dose/Day 57.
✕ History of myocarditis, pericarditis, or myopericarditis prior to Day 1.
✕ Has previously received an investigational EBV vaccine.
✕ Note: Other inclusion and exclusion criteria may apply.

Source: ClinicalTrials.gov · NCT07478952 · last updated 2026-03-24